Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Apr 01, 2026
TickeronGET DAILY SIGNALS
Why Is Turning Point Brands (TPB) Stock Down -15% Today?

Why Is Turning Point Brands (TPB) Stock Down -15% Today?

Key Takeaways

  • Shares of Turning Point Brands (TPB) are falling sharply intraday on April 1, 2026, shedding approximately 15% from their prior session close of roughly $87.41, placing the stock near $74.30
  • The primary catalyst is broad investor risk-off selling tied to mounting trade-policy uncertainty ahead of President Trump's sweeping tariff announcements scheduled for April 2 — a day the administration has branded "Liberation Day"
  • TPB carries compounding headwinds from its March 2 earnings release, where GAAP EPS of $0.42 sharply missed the $0.87 consensus, and management issued soft Q1 2026 EBITDA guidance of $24–$27 million
  • Heavy SG&A investment (+38% year-over-year in Q4 2025) tied to the Modern Oral expansion is pressuring near-term profitability, even as revenue grew 29% and the Modern Oral segment surged 266%
  • Zacks Research downgraded TPB to "Strong Sell" in early March, adding persistent analyst skepticism to the bearish backdrop
  • Traders are watching Q1 2026 results, any FDA news related to TPB's pending nicotine pouch PMTA, and how the company's import-linked supply chain responds to new tariff structures

Opening Summary

Turning Point Brands, Inc. (TPB) is a Louisville, Kentucky-based manufacturer, marketer, and distributor of alternative tobacco and nicotine consumer products, including its rapidly expanding Modern Oral segment built around FRE-branded white nicotine pouches, as well as the legacy Stoker's moist snuff and loose leaf tobacco lines. On April 1, 2026, shares are tumbling approximately 15% intraday, falling from the prior session's close of approximately $87.41 to around $74.30 during active trading. The sharp move lower reflects a convergence of macro-driven selling tied to imminent tariff policy developments and persistent post-earnings sentiment damage that has shadowed the stock since early March.

Liberation Day Tariff Fears

The dominant force moving virtually all consumer goods and manufactured product equities today is the looming announcement from the Trump administration of broad reciprocal tariffs, scheduled for April 2. Markets broadly sold off on April 1 in anticipation, with the risk-off rotation hitting mid-cap consumer staples and specialty tobacco names particularly hard. TPB is directly exposed to this uncertainty: management had already flagged on the Q4 2025 earnings call that elevated tariff costs were affecting margins in the Stoker's segment, and investors are now pricing in the possibility that new tariff structures could further compress gross margins across both the traditional tobacco and Modern Oral product lines. Any supply chain disruption tied to imported components for the FRE pouch manufacturing platform amplifies that concern.

Post-Earnings Overhang Deepens

TPB) entered today's session carrying significant unresolved damage from its March 2, 2026 Q4 2025 earnings release, which triggered a sell-off of more than 20% in a single session. While adjusted EPS of $0.95 modestly beat the $0.87 consensus and revenue of $121.0 million topped estimates, GAAP EPS came in at just $0.42 versus an expected $0.87 — a gap that rattled institutional holders and raised concerns about the true cost of the company's aggressive Modern Oral buildout. SG&A expenses climbed 38% year-over-year in Q4, driven by marketing spend, compliance costs, freight, and production capacity investment. Investors are re-evaluating whether the transition from legacy tobacco products to nicotine pouches can be executed profitably, even as the volume trajectory remains impressive.

Weak Q1 2026 Guidance and Margin Uncertainty

Management's Q1 2026 adjusted EBITDA guidance range of $24–$27 million was notably below what many analysts had modeled, and the company indicated that investment timing would make EBITDA visibility "lumpy" throughout 2026. This is weighing heavily on sentiment today, as the soft guidance suggests that the profitability trough from the Modern Oral ramp may not yet be behind the company. With Zacks having downgraded TPB to "Strong Sell" and several other analysts revising their models lower, the stock enters any fresh macro shock without a supportive analyst consensus buffer to cushion the blow.

Insider Selling and Institutional Pressure

Compounding the macro and fundamental headwinds, recent insider activity has added a bearish overlay. The company's chairman sold 30,000 shares in the period following the Q4 earnings release, and a director also reduced holdings — moves closely tracked by retail and institutional investors alike. Despite institutional ownership remaining elevated at approximately 96%, large block sales following the earnings miss contributed to elevated volume and downward price pressure. Today's tariff-driven sell-off is arriving at a technically vulnerable moment for the stock, which had been attempting to stabilize between $86 and $90 after falling from a 52-week high of $146.90.

Market Context and Trading Activity

Today's session for TPB is occurring against a backdrop of broad-based equity market weakness, with indices falling as investors position for tariff-related macro uncertainty. The sector ETF most closely associated with tobacco and consumer staples is also under pressure, meaning TPB's move is not entirely idiosyncratic. However, the magnitude of TPB's decline exceeds the broader sector move, suggesting company-specific factors — the earnings miss, the margin investment cycle, and tariff exposure in Stoker's — are amplifying the macro-driven selling. Volume today is tracking well above the stock's average daily volume of approximately 329,000 shares, consistent with a forced or panic-driven liquidation event rather than routine turnover. Technically, the stock has broken through multiple short-term support levels that had been established during the post-earnings stabilization phase.

Trending AI Robots

For traders navigating volatile sessions like today's, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots covering thousands of tickers across multiple strategies, timeframes, and asset classes — but only those demonstrating the strongest real-time performance metrics are featured in the Trending section. Each bot is differentiated by its traded symbols, risk profile, holding period, and win-rate statistics, giving traders the ability to match a bot's approach to their own preferences. Whether the market environment favors momentum, mean reversion, or defensive positioning, the Trending AI Robots section surfaces the strategies proving most effective right now. Traders looking to complement their own analysis with systematic, data-driven tools may find this resource particularly valuable during high-volatility periods.

What Comes Next for TPB

The most immediate event on TPB's calendar is the Q1 2026 earnings release, which will be the first real test of whether management's front-loaded investment thesis is tracking in line with the $180–$190 million Modern Oral net revenue guidance for the full year. Any upside surprise on EBITDA margins or FRE nicotine pouch market share data could catalyze a meaningful recovery; a miss would likely accelerate selling. Separately, TPB's pending PMTA for its FRE pouch line remains a pivotal regulatory overhang — approval would validate the product's long-term commercial pathway, while a denial or delay would cast doubt on the entire Modern Oral growth strategy. Tariff policy will remain a near-term variable affecting input costs for both the Stoker's and Modern Oral segments. Analysts will also be scrutinizing whether the pace of insider selling continues, and whether the institutional ownership base shows any further signs of structural rotation away from the name.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: TPB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TPB in downward trend: 10-day moving average broke below 50-day moving average on November 13, 2026

The 10-day moving average for TPB crossed bearishly below the 50-day moving average on November 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TPB as a result. In 48 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for TPB turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 27 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.

TPB moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPB advanced for three days, in 231 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

TPB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 162 of 222 cases where TPB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.071) is normal, around the industry mean (-7.297). P/E Ratio (28.154) is within average values for comparable stocks, (12.512). Projected Growth (PEG Ratio) (0.048) is also within normal values, averaging (3.595). Dividend Yield (0.005) settles around the average of (0.060) among similar stocks. P/S Ratio (2.701) is also within normal values, averaging (2.780).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. TPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

Notable companies

The most notable companies in this group are Philip Morris International (NYSE:PM), Altria Group (NYSE:MO).

Industry description

The industry is engaged in the growth, preparation for sale, advertisement, and distribution of tobacco and tobacco-related products like cigarettes. In 2017, tobacco companies spent an estimated $9.36 billion marketing cigarettes and smokeless tobacco in the U.S. – an amount that translates to more than $25 million each day (according to a CDC report). Philip Morris International Inc., Altria Group Inc., and British American Tobacco plc are some major cigar makers. In recent times, vaping or the use of e-cigarette (does not burn tobacco) is gaining momentum – several established cigarette makers are trying to expand their footprint in this new market.

Market Cap

The average market capitalization across the Tobacco Industry is 57.21B. The market cap for tickers in the group ranges from 99 to 308.42B. PM holds the highest valuation in this group at 308.42B. The lowest valued company is AHII at 99.

High and low price notable news

The average weekly price growth across all stocks in the Tobacco Industry was -19%. For the same Industry, the average monthly price growth was -24%, and the average quarterly price growth was -35%. MO experienced the highest price growth at -5%, while XXII experienced the biggest fall at -56%.

Volume

The average weekly volume growth across all stocks in the Tobacco Industry was 90%. For the same stocks of the Industry, the average monthly volume growth was 50% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 40
P/E Growth Rating: 52
Price Growth Rating: 70
SMR Rating: 73
Profit Risk Rating: 71
Seasonality Score: 35 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of tobacco products

Industry Tobacco

Industry
Tobacco
Address
5201 Interchange Way
Phone
+1 502 778-4421
Employees
484
Web
https://www.turningpointbrands.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.